Pneumocystis carinii pneumonia

June 1997
MMWR: Morbidity & Mortality Weekly Report;6/27/1997 Supplement RR-12, Vol. 46, p4
Provides information on the disease pneumocystis carinii pneumonia. Recommendation made by authorities relating to the prevention of exposure to disease; Precautions that should be considered by adolescents, adults and pregnant women.


Related Articles

  • 1995 revised guidelines for prophylaxis against Pneumocystis carinii pneumonia for children...  // MMWR: Morbidity & Mortality Weekly Report;4/28/95 Supplement RR-4, Vol. 44 Issue 16, p1 

    Presents the revised prevention guidelines for prophylaxis against Pneumocystis carinii pneumonia (PCP) for children infected with or perinatally exposed to human immunodeficiency virus (HIV). Recommendations including the prompt diagnosis of children born to HIV-infected women; Timing and...

  • Prophylactic Treatment of P. Carinii Pneumonia. Walling, Anne D. // American Family Physician;2/15/2000, Vol. 61 Issue 4, p1145 

    Highlights the study `Efficacy of Azithromycin in Prevention of Pneumocystis carinii pneumonia: A Randomised Trial,' by M.W. Dunne and colleagues published in the September 11, 1999 issue of `Lancet.'

  • Clinic HIV-focused features and prevention of Pneumocystis carinii pneumonia. Turner, Barbara J.; Md; Markson, Leona; Cocroft, James; Cosler, Leon; Hauck, Walter W.; Turner; Turner, B J; Markson, L; Cocroft, J; Cosler, L; Hauck, W W // JGIM: Journal of General Internal Medicine;Jan1998, Vol. 13 Issue 1, p16 

    Objective: To examine the association of clinic HIV-focused features and advanced HIV care experience with Pneumocystis carinii pneumonia (PCP) prophylaxis and development of PCP as the initial AIDS diagnosis.Design: Nonconcurrent prospective study.Setting:...

  • PNEUMOCYSTIS CARINII PNEUMONIA CHEMOPROPHYLAXIS IN HIV+ PATIENTS IN GLASGOW: AN AUDIT. Wardle, D.M.; Kennedy, D. // Sexually Transmitted Infections;Jun2003 Supplement 1, Vol. 79, pA22 

    Introduction: We audited chemoprophylactic use against Pneumocystis carinii pneumonia (PCP) in our HIV+ patients using US Public Health Service and Infectious Diseases Society of America USPHS/IDSA guidelines as a standard in the absence of definitive UK guidelines. Methods: Criteria for...

  • Diagnostic and Therapeutic Technology Assessment (DATTA).  // JAMA: Journal of the American Medical Association;5/9/90, Vol. 263 Issue 18, p2510 

    Discusses the use of aerosolized pentamidine in preventing recurrent Pneumocystis carnii infection in HIV-positive patients. Mechanism of action of the drug; Effectiveness and safety of the drug; Method of delivery of aerosolized pentamidine.

  • PCP prophylaxis with use of corticosteroids by neurologists. Kelly, Dearbhla M.; Cronin, Simon // Practical Neurology (BMJ Publishing Group);Apr2014, Vol. 14 Issue 2, p74 

    Pneumocystis jirovecii pneumonia (PCP) is increasingly reported in patients without HIV. Corticosteroids are a major risk factor, with up to 90% of patients receiving corticosteroid treatment prior to the development of PCP. In view of this, many specialties now prescribe PCP prophylaxis to...

  • Point prevalence of Pneumocystis pneumonia in patients with non-Hodgkin lymphoma according to the number of cycles of R-CHOP chemotherapy. Kim, Tark; Choi, Sang-Ho; Kim, Sung-Han; Jeong, Jin-Yong; Woo, Jun; Kim, Yang; Sung, Heungsup; Kim, Mi-Na; Yoon, Dok; Suh, Cheolwon; Lee, Sang-Oh // Annals of Hematology;Feb2013, Vol. 92 Issue 2, p231 

    R-CHOP chemotherapy composed of rituximab, cyclophosphamide, adriamycin, vincristine, and prednisolone which might increase the risk of Pneumocystis pneumonia in patients with non-Hodgkin lymphoma. We estimated the point prevalence of Pneumocystis pneumonia in non-Hodgkin lymphoma patients...

  • Should Pneumocystis jiroveci prophylaxis be recommended with Rituximab treatment in ANCA-associated vasculitis? Besada, Emilio; Nossent, Johannes // Clinical Rheumatology;Nov2013, Vol. 32 Issue 11, p1677 

    Reports in haematology, transplantation medicine and rheumatology indicate that Rituximab, a B cell depleting therapy, increases the risk for Pneumocystis jiroveci pneumopathy. Patients with antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis have an increased incidence of P....

  • Avoiding the risk. Jesitus, John // Dermatology Times;Feb2013, Vol. 34 Issue 2, p27 

    The article explains the importance of considering pneumocystis pneumonia (PCP) prophylaxis in certain immunosuppressed patients, according to Doctor Amer N. Kalaaji, an associate professor of dermatology at the Mayo Clinic in Rochester, Minnesota. One study showed that the development of PCP...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics